- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- PR positive
- KRAS positive
- PR negative
- ER negative
- BRAF positive
- EGFR negative
- PD-L1 negative
- IDH positive
- p16 positive
- CD19 positive
- HLA-A positive
- BRCA1 positive
- ALK negative
- BRCA2 positive
- ALK positive
- CD20 positive
- HLA positive
- IDH negative
- MET positive
- TP53 positive
- ROS1 positive
- MYC positive
- HR positive
- HLA negative
- MSI-H positive
- FLT3 positive
- PALB2 positive
- p16 negative
- ROS1 negative
- BRAF negative
- RB1 negative
- RB1 positive
- HLA-A negative
- NRAS positive
- HPV positive
- dMMR positive
- NF1 positive
- PIK3CA positive
- RET positive
- BRCA positive
- MET negative
- CD22 positive
- RAS positive
- ATM positive
- BCL2 positive
- NTRK positive
- HPV negative
- MGMT negative
- BCL6 positive
- CFTR positive
- MLH1 positive
- MSH6 positive
- CD30 positive
- MSH2 positive
- PMS2 positive
- ARID1A positive
- KRAS negative
- MMR positive
- anti-dsDNA positive
- BCR-ABL1 positive
- BRIP1 positive
- CCND1 positive
- KIT positive
- PTEN positive
- Philadelphia chromosome positive
- ANA positive
- CHEK2 positive
- HRAS positive
- HbSS positive
- MGMT positive
- NPM1 positive
- CD123 positive
- PD-1 positive
- RAS negative
- ctDNA positive
- CD33 positive
- FGFR2 positive
- KMT2A positive
- RAD51 positive
- RAD51C positive
- HBV DNA negative
- MTAP positive
- NTRK1 positive
- RAD51D positive
- RET negative
- EPCAM positive
- FGFR3 positive
- HBsAg positive
- MSI positive
- MSS positive
- PD-1 negative
- STK11 positive
- anti-Sm positive
- p53 positive
- t(11;14) positive
- AR positive
- ASXL1 positive
- BRCA negative
- CDK4 positive
- CLDN18.2 positive
- FGFR positive
- GPC3 positive
- HBV DNA positive
- HBsAg negative
- MMR negative
- MSI negative
- MSI-H negative
- NF2 positive
- NRAS negative
- RUNX1 positive
- TP53 negative
- ZnT8 positive
- BARD1 positive
- CD19 negative
- CD3 positive
- FANCA positive
- HPV16 positive
- MSS negative
- NTRK negative
- APC positive
- APOE ε4 positive
- BCR-ABL positive
- CD4 positive
- DMD positive
- EZH2 positive
- FLT3 negative
- FMR1 positive
- HR negative
- HbSC positive
- IA-2 positive
- JAK2 positive
- PDGFRA positive
- RAF positive
- RF positive
- SMARCA4 positive
- SMN1 positive
- T790M positive
- dMMR negative
- ABCA4 positive
- BAP1 positive
- BRCA1 negative
- BRCA2 negative
- CCNE1 positive
- CD4 count positive
- CD5 positive
- CD70 positive
- CDK12 positive
- CEA positive
- DLL3 positive
- Del(17p) positive
- EBV positive
- GATA2 positive
- GRN positive
- HBcAb negative
- Ki-67 positive
- MECP2 positive
- NF1 negative
- PTEN negative
- PTPN11 positive
- Ph positive
- RAD54L positive
- TERT positive
- TROP2 positive
- pMMR positive
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- \-7 positive
- AKT1 positive
- APOL1 positive
- B7-H3 positive
- CD38 positive
- CDK6 positive
- CHEK1 positive
- CLDN6 positive
- COL7A1 positive
- DMPK positive
- DNMT3A positive
- ER or PR positive
- FANCL positive
- FRα positive
- H3K27M positive
- HBB positive
- HBcAb positive
- HRD positive
- HbSβ0-thalassemia positive
- ICA positive
- L858R positive
- MDM2 positive
- MLH1 negative
- MLL rearrangement positive
- MSH2 negative
- MSH6 negative
- NBN positive
- PAH positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Grade 5
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 or more Spontaneous Breathing Trials (SBTs)
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Activity Modification
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Radiation Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Alectinib for ALK
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
19420 trials
1
2
3
…50